Abstract

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy in recent years. They have extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious in tumor patients, have become pioneer drugs in the field of tumor immunotherapy since they were incorporated into clinical practice. In addition, γδT cells that have infiltrated into tumor tissues are found to be in a state of exhaustion or anergy, and there is upregulation of many immune checkpoints (ICs) on their surface, suggesting that γδT cells have a similar ability to respond to ICIs as traditional effector T cells. Studies have shown that targeting ICs can reverse the dysfunctional state of γδT cells in the tumor microenvironment (TME) and exert antitumor effects by improving γδT-cell proliferation and activation and enhancing cytotoxicity. Clarification of the functional state of γδT cells in the TME and the mechanisms underlying their interaction with ICs will solidify ICIs combined with γδT cells as a good treatment option.

Details

Title
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Author
Gao, Zhifei; Bai, Yifeng; Lin, Anqi; Jiang, Aimin; Zhou, Chaozheng; Cheng, Quan; Liu, Zaoqu; Chen, Xin; Zhang, Jian; Luo, Peng
Pages
1-23
Section
Review
Publication year
2023
Publication date
2023
Publisher
BioMed Central
e-ISSN
14764598
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2777785051
Copyright
© 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.